Clinical utility of anti-p53 auto-antibody: Systematic review and focus on colorectal cancer

doi:10.3748/wjg.v19.i29.4651

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 29

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9847)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

528

HTML

7479

Figures (1-3)

162

Tables (1-6)

261

Sum=8430

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

852

Download

565

Sum=1417

Aug 7, 2013 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (44)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Aug 7, 2013; 19(29): 4651-4670
Published online Aug 7, 2013. doi: 10.3748/wjg.v19.i29.4651

Table 4 Combined carcino-embryonic antigen and anti-p53 auto-antibody rates from all studies reporting the presence of both markers (n = 1192) n (%)

	CEA normal	CEA elevated
Anti-p53 ab present	112 (9.4)	90 (7.6)
Anti-p53 ab absent	584 (48.9)	406 (34.1)

CEA: Carcino-embryonic antigen.

Citation: Suppiah A, Greenman J. Clinical utility of anti-p53 auto-antibody: Systematic review and focus on colorectal cancer. World J Gastroenterol 2013; 19(29): 4651-4670
URL: https://www.wjgnet.com/1007-9327/full/v19/i29/4651.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i29.4651